629 related articles for article (PubMed ID: 30426903)
1. Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
Zhongqi F; Xiaodong S; Yuguo C; Guoyue L
Anticancer Agents Med Chem; 2019; 19(2):222-228. PubMed ID: 30426903
[TBL] [Abstract][Full Text] [Related]
2. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
Lee YH; Tai D; Yip C; Choo SP; Chew V
Front Immunol; 2020; 11():568759. PubMed ID: 33117354
[TBL] [Abstract][Full Text] [Related]
3. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
4. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
Hato T; Goyal L; Greten TF; Duda DG; Zhu AX
Hepatology; 2014 Nov; 60(5):1776-82. PubMed ID: 24912948
[TBL] [Abstract][Full Text] [Related]
7. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for hepatocellular carcinoma: Current and future.
Johnston MP; Khakoo SI
World J Gastroenterol; 2019 Jun; 25(24):2977-2989. PubMed ID: 31293335
[TBL] [Abstract][Full Text] [Related]
9. Toward a postbiotic era of microbiome science: Opportunities to advance immunotherapies for hepatocellular carcinoma.
Nakatsu G
J Gastroenterol Hepatol; 2022 Jan; 37(1):34-38. PubMed ID: 34665475
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
Shen KY; Zhu Y; Xie SZ; Qin LX
J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
[TBL] [Abstract][Full Text] [Related]
12. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
Ng HHM; Lee RY; Goh S; Tay ISY; Lim X; Lee B; Chew V; Li H; Tan B; Lim S; Lim JCT; Au B; Loh JJH; Saraf S; Connolly JE; Loh T; Leow WQ; Lee JJX; Toh HC; Malavasi F; Lee SY; Chow P; Newell EW; Choo SP; Tai D; Yeong J; Lim TKH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847986
[TBL] [Abstract][Full Text] [Related]
14. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
15. Immunological landscape and immunotherapy of hepatocellular carcinoma.
Prieto J; Melero I; Sangro B
Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):681-700. PubMed ID: 26484443
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.
Jiang Y; Han QJ; Zhang J
World J Gastroenterol; 2019 Jul; 25(25):3151-3167. PubMed ID: 31333308
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic approaches for hepatocellular carcinoma.
Longo V; Gnoni A; Casadei Gardini A; Pisconti S; Licchetta A; Scartozzi M; Memeo R; Palmieri VO; Aprile G; Santini D; Nardulli P; Silvestris N; Brunetti O
Oncotarget; 2017 May; 8(20):33897-33910. PubMed ID: 28420805
[TBL] [Abstract][Full Text] [Related]
18. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
19. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
20. Potentiality of immunotherapy against hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
